Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPECTRA-HFpEF: Vicadrostat/Empagliflozin vs Empagliflozin vs Empagliflozin/Spironolactone in HFpEF
NCT07857772Phase 2Not yet recruiting
- Sponsor
- Baim Institute for Clinical Research
- Start
- Mar 2027
- Primary completion
- May 2028
01
Overview
A Phase 2 trial of vicadrostat in heart failure with preserved ejection fraction (HFpEF), sponsored by Baim Institute for Clinical Research. Planned start Mar 2027; status: not yet recruiting.
02
Drugs
vicadrostat
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT07857772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07857772.